REGENXBIO (RGNX) News Today $7.27 -0.09 (-1.22%) Closing price 04:00 PM EasternExtended Trading$7.18 -0.09 (-1.29%) As of 04:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period REGENXBIO (RGNX) Expected to Announce Quarterly Earnings on TuesdayREGENXBIO (NASDAQ:RGNX) will be releasing earnings before the market opens on Tuesday, February 25, Financial Modeling Prep reports.February 18 at 4:37 AM | marketbeat.comREGENXBIO (NASDAQ:RGNX) Cut to "Sell" at StockNews.comFebruary 15, 2025 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Lowered to Sell Rating by StockNews.comStockNews.com downgraded REGENXBIO from a "hold" rating to a "sell" rating in a report on Saturday.February 15, 2025 | marketbeat.comGoldman Sachs Downgrades REGENXBIO (RGNX)February 11, 2025 | msn.comGoldman Sachs cuts Regenxbio stock rating, slashes price targetFebruary 11, 2025 | msn.comRegenxbio downgraded to Neutral from Buy at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comRegenXBio (RGNX) was downgraded to a Hold Rating at Goldman SachsFebruary 11, 2025 | markets.businessinsider.comThe Goldman Sachs Group Downgrades REGENXBIO (NASDAQ:RGNX) to NeutralThe Goldman Sachs Group lowered REGENXBIO from a "buy" rating to a "neutral" rating and decreased their price target for the stock from $38.00 to $14.00 in a research note on Tuesday.February 11, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Stock Rating Upgraded by Raymond JamesRaymond James upgraded REGENXBIO to a "moderate buy" rating in a research report on Thursday.February 8, 2025 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Rating Increased to Hold at StockNews.comStockNews.com raised REGENXBIO from a "sell" rating to a "hold" rating in a report on Friday.February 7, 2025 | marketbeat.comRaymond James Initiates Coverage on REGENXBIO (NASDAQ:RGNX)Raymond James initiated coverage on shares of REGENXBIO in a report on Friday. They set an "outperform" rating and a $27.00 price target on the stock.February 7, 2025 | marketbeat.comRaymond James sets $27 target for Regenxbio stockFebruary 6, 2025 | msn.comRegenxbio resumed with an Outperform at Raymond JamesFebruary 6, 2025 | markets.businessinsider.comWith 71% ownership of the shares, REGENXBIO Inc. (NASDAQ:RGNX) is heavily dominated by institutional ownersFebruary 4, 2025 | finance.yahoo.comFY2026 EPS Estimates for REGENXBIO Lifted by Leerink PartnrsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Investment analysts at Leerink Partnrs lifted their FY2026 EPS estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, January 29th. Leerink Partnrs analyst M. Foroohar now anticipates that the biotechnology company wFebruary 3, 2025 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold recommendation and eleven have given a buy recommJanuary 31, 2025 | marketbeat.comREGENXBIO Announces Presentations of RGX-121 at the 21st Annual WORLDSymposium 2025January 30, 2025 | prnewswire.comLeerink Partnrs Forecasts Higher Earnings for REGENXBIOREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities researchers at Leerink Partnrs increased their FY2024 earnings estimates for REGENXBIO in a research report issued to clients and investors on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar now forecasts that the biotechnology coJanuary 24, 2025 | marketbeat.comLeerink Partnrs Estimates REGENXBIO FY2029 EarningsREGENXBIO Inc. (NASDAQ:RGNX - Free Report) - Equities research analysts at Leerink Partnrs issued their FY2029 EPS estimates for shares of REGENXBIO in a report issued on Wednesday, January 22nd. Leerink Partnrs analyst M. Foroohar forecasts that the biotechnology company will post earnings per sJanuary 23, 2025 | marketbeat.comRegenXBio (RGNX) Gets a Buy from RBC CapitalJanuary 22, 2025 | markets.businessinsider.comREGENXBIO (NASDAQ:RGNX) Receives "Outperform" Rating from Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and set a $30.00 price target on shares of REGENXBIO in a research note on Tuesday.January 21, 2025 | marketbeat.comAssenagon Asset Management S.A. Has $6.62 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)Assenagon Asset Management S.A. boosted its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 53.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 856,572 shares of the biotechnology company's stock after acquiring an additional 296,700 shaJanuary 20, 2025 | marketbeat.comRegenxbio Secures A Partnership With Nippon Shinyaku For RGX-111 & 121January 16, 2025 | seekingalpha.comRegenXBio: Strategic Partnerships and Promising Pipeline Drive Buy RatingJanuary 16, 2025 | markets.businessinsider.comRegenxbio Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)January 15, 2025 | benzinga.comHC Wainwright Reiterates "Buy" Rating for REGENXBIO (NASDAQ:RGNX)HC Wainwright reissued a "buy" rating and set a $36.00 price target on shares of REGENXBIO in a research report on Wednesday.January 15, 2025 | marketbeat.comBank of America Securities Sticks to Their Buy Rating for RegenXBio (RGNX)January 15, 2025 | markets.businessinsider.comRegenxbio stock surges on strategic partnership deal with Nippon ShinyakuJanuary 14, 2025 | investing.comREGENXBIO partners with Nippon Shinyaku for MPS therapiesJanuary 14, 2025 | msn.comRegenxbio, Nippon Shinyaku enter commercialization pact for RGX-121January 14, 2025 | markets.businessinsider.comRockville’s RegenxBio strikes potential $810M deal with Japan’s Nippon ShinyakuJanuary 14, 2025 | bizjournals.comStrategic Partnerships and Promising Pipeline Drive Buy Rating for RegenXBioJanuary 14, 2025 | markets.businessinsider.comRegenXBio Partners with Nippon Shinyaku on Gene TherapiesJanuary 14, 2025 | tipranks.comREGENXBIO and Nippon Shinyaku Announce Exclusive Partnership to Develop and Commercialize RGX-121 and RGX-111 for MPS DiseasesJanuary 14, 2025 | prnewswire.comAbbVie, Regenxbio provide updates on ABBV-RGX-314 clinical programJanuary 13, 2025 | markets.businessinsider.comAbbVie and REGENXBIO Announce Updates on the ABBV-RGX-314 Clinical ProgramJanuary 13, 2025 | prnewswire.comJPMorgan Chase & Co. Decreases Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)JPMorgan Chase & Co. cut its stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 17.8% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,477,311 shares of the biotechnology company's stock after selling 535,165 sharJanuary 8, 2025 | marketbeat.comRegenxbio price target lowered to $22 from $25 at BofAJanuary 7, 2025 | markets.businessinsider.comRegenxbio price target lowered to $30 from $35 at RBC CapitalJanuary 7, 2025 | markets.businessinsider.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from BrokeragesREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has received a consensus rating of "Moderate Buy" from the twelve ratings firms that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The avJanuary 6, 2025 | marketbeat.comBarclays PLC Purchases 67,948 Shares of REGENXBIO Inc. (NASDAQ:RGNX)Barclays PLC increased its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 141.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 116,024 shares of the biotechnology compaDecember 30, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Short Interest Up 18.4% in DecemberREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a significant growth in short interest in December. As of December 15th, there was short interest totalling 6,230,000 shares, a growth of 18.4% from the November 30th total of 5,260,000 shares. Based on an average daily volume of 1,020,000 shares, the days-to-cover ratio is currently 6.1 days.December 30, 2024 | marketbeat.comState Street Corp Has $29.19 Million Position in REGENXBIO Inc. (NASDAQ:RGNX)State Street Corp decreased its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 3.1% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,782,883 shares of the biotechnology company's stock after sellingDecember 22, 2024 | marketbeat.comNational Bank of Canada FI Purchases Shares of 68,000 REGENXBIO Inc. (NASDAQ:RGNX)National Bank of Canada FI bought a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 68,000 shares of the biotechnoloDecember 15, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by AnalystsREGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the twelve ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and eleven have issued a buy recoDecember 12, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for RegenXBio (RGNX)December 11, 2024 | markets.businessinsider.comJacobs Levy Equity Management Inc. Lowers Stock Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Jacobs Levy Equity Management Inc. cut its holdings in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 41.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 89,218 shares of the biotechnology company's stock afDecember 9, 2024 | marketbeat.comRedmile Group LLC Has $51.33 Million Holdings in REGENXBIO Inc. (NASDAQ:RGNX)Redmile Group LLC grew its position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) by 7.1% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 4,892,902 shares of the biotechnology company's stock aftDecember 5, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Makes New $643,000 Investment in REGENXBIO Inc. (NASDAQ:RGNX)Connor Clark & Lunn Investment Management Ltd. acquired a new stake in REGENXBIO Inc. (NASDAQ:RGNX - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 61,288 shares of the biotechnology company's stock, valued at approximately $6November 29, 2024 | marketbeat.com3 Best Stocks to Buy Now, 11/21/2024, According to Top AnalystsNovember 21, 2024 | msn.com Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address RGNX Media Mentions By Week RGNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. RGNX News Sentiment▼-0.280.60▲Average Medical News Sentiment RGNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. RGNX Articles This Week▼35▲RGNX Articles Average Week Get REGENXBIO News Delivered to You Automatically Sign up to receive the latest news and ratings for RGNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies KNSA News DYN News GPCR News ARDX News INDV News NRIX News VIR News SNDX News ARVN News ANIP News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:RGNX) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding REGENXBIO Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share REGENXBIO With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RGNX Stock Alerts